Grace Therapeutics (GRCE): Can Shares Reach the $6 Analyst Target?

Key Takeaways

• The $6 central target is the arithmetic mean of two verified, current analyst price targets: $4 from Craig-Hallum and $8 from TD Cowen.
• With shares near $1.81, reaching $6 would require a gain of roughly 230%, a very large move for any listed security.
• The analyst target range is unusually wide — $4 to $8, a two-to-one spread that reflects deep uncertainty about the regulatory path.
• The strongest support is that the FDA's rejection of GTx-104 was manufacturing-related, not clinical; no additional patient data was requested.
• The biggest risks are the unknown timing of a resubmission, a micro-cap balance sheet, and potential dilution.
• You can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
• For automated, AI-driven trade ideas across thousands of stocks and ETFs, explore Trending AI Robots.

Analyst Targets and What They Mean for GRCE

GRCE is the ticker for Grace Therapeutics, Inc., a late-stage biopharmaceutical company formerly known as Acasti Pharma. Sell-side coverage of this micro-cap remains thin. Two current analyst price targets could be verified: Craig-Hallum, which lowered its target to $4 from $11 while maintaining a Buy rating following the Complete Response Letter (CRL), and TD Cowen, whose analyst Stacy Ku cut the target to $8 from $12 while also retaining a Buy. The arithmetic mean of these two figures is $6, which serves as the central target used here.

The $4-to-$8 range is wide, and the two firms' reasoning differs in degree rather than kind. Both acknowledge that the Phase 3 STRIVE-ON data supporting GTx-104 remain intact and that the FDA did not ask for new clinical data. The gap between targets largely reflects different assumptions about the probability and timing of a successful resubmission and eventual approval. This is an analyst-derived average, not a guarantee, and it should be read as a rough gauge of Wall Street sentiment rather than a precise forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where GRCE Stands Today and the Path to $6

Grace Therapeutics shares trade around $1.81, near the lower end of a 52-week range of $1.67 to $5.18 and down roughly 48% year to date. At $1.81, a move to $6 implies upside of about 230% — an unusually large required gain that sits well beyond the stock's recent trading band. The path would almost certainly hinge on a binary catalyst: a successful New Drug Application (NDA) resubmission for GTx-104 and, ultimately, FDA approval.

In April 2026 the FDA issued a CRL citing Chemistry, Manufacturing, and Controls (CMC) items and non-clinical information — specifically leachables data, excipient toxicology assessments, and cGMP (current good manufacturing practice) compliance at a contract manufacturer — rather than any efficacy or safety concern. The company has since received Type A meeting minutes, adopted a dual-source manufacturing strategy, and raised about $10 million at $2.10 per share to fund remediation. Reaching $6 would require investors to price in a much higher probability of approval than today's valuation implies.

Supports That Could Help Close the Gap

Several factors underpin the more optimistic targets. The FDA's CRL was manufacturing- and packaging-focused, and the agency did not request additional clinical data, leaving the pivotal STRIVE-ON results — which met their primary endpoint — unchallenged. GTx-104 also holds Orphan Drug Designation, which could provide seven years of U.S. marketing exclusivity if approved. Management reported roughly $22.2 million in cash as of August 11, 2026, and has guided that it can fund operations through the end of 2028, reducing near-term financing pressure. Insider buying and the dual-source manufacturing plan signal confidence in a resubmission path.

Risks That Could Keep the Target Out of Reach

The obstacles are equally real. There is no guaranteed timetable for resubmission, and an FDA reinspection of the current contract manufacturer is outside the company's control. The wide $4-to-$8 analyst spread reflects genuine uncertainty, and the lower target implies only a partial recovery. As a pre-revenue company with a market capitalization near $39 million, Grace Therapeutics remains exposed to dilution if additional capital is needed, and its shares are highly sensitive to regulatory headlines. Any new clinical, CMC, or financing setback could sharply reset expectations.

Technical Picture and Key Levels to Watch

The stock's technical backdrop is weak. GRCE trades below its 200-day moving average after falling from the April 2026 high of $5.18 to an October 2026 low of $1.67. The $5.18 level represents the prior peak and a natural long-term resistance zone, while the $1.67 low serves as key support. On any recovery, the psychologically significant $2 and $3 levels, followed by the $5 area, would be the notable hurdles before the $6 target comes into view.

Time Horizon and Items to Monitor

Analyst price targets typically reflect a roughly 12-month horizon, though for a company awaiting a regulatory decision, the actual catalyst calendar matters more than any fixed date. Key items to watch include the completion of required non-clinical studies, progress on the second U.S.-based manufacturing source, any FDA reinspection outcome, the classification of the resubmission (a Class 1 review carries a shorter clock than Class 2), and the company's quarterly cash position and any further financings. From what I see, the regulatory milestones will drive the next major move.

Using AI Daily Buy/Sell Signals in Practice

For traders seeking a data-driven complement to fundamental research, Tickeron's AI Daily Buy/Sell Signals continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help users discover opportunities, track positions, and spot shifting trends more efficiently than manual screening. Those who want automated, around-the-clock market monitoring can explore AI Daily Buy/Sell Signals to see how the approach fits their workflow. I find it helpful for keeping tabs on names like GRCE when regulatory events are in play.

Final Assessment

Can Grace Therapeutics stock reach $6? The question rests almost entirely on a single regulatory outcome. The $6 figure is the average of two current analyst targets spanning $4 to $8, and it sits roughly 230% above the present share price — a very large move that would require investors to dramatically re-rate the probability of GTx-104 approval. The clinical data, Orphan Drug Designation, and extended cash runway are genuine supports, but manufacturing remediation, FDA reinspection, and dilution risk remain substantial obstacles. Analysts disagree on the scale of the recovery, and no one can say with certainty whether or how quickly a resubmission succeeds. Investors should focus on the regulatory milestones and financing events rather than treating the $6 target as a likely destination.

Exploring Tickeron AI Tools

In my own research process, I often turn to Tickeron’s suite of AI tools to cross-check ideas and surface additional context across the market. The AI Daily Buy/Sell Signals platform has been particularly useful for tracking signals on micro-cap names and seeing how sentiment shifts around key events. It provides a structured way to monitor positions without replacing core fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume